LAMDA PHARMA LIMITED
Company number 09421468 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Risk Rating: MEDIUM
Justification: LAMDA PHARMA LIMITED is an active private limited company with statutory filings currently up to date and no insolvency proceedings. However, it is classified as a non-trading company with nominal share capital of £1, and the available data contains no balance sheet, profit and loss, or cash flow figures. Its status as an audit exemption subsidiary, with a corporate person with significant control holding over 75% of voting rights, indicates dependence on a parent entity, but solvency and liquidity cannot be verified without financial statements.
Key Concerns
-
No financial data provided: The company information includes no balance sheet, current assets, current liabilities, or cash position. With share capital of only £1, net assets and working capital are unknown, making it impossible to confirm whether the company can meet its obligations.
-
Non-trading status: The SIC code (74990 Non-trading company) indicates the company undertakes no trading activity and generates no operating revenue. Its sustainability therefore depends on support from its parent, Quantum Pharma Group Limited, or on non-operating assets that are not disclosed.
-
Recent board change: A director resigned on 5 October 2026. For a small company with a limited officer base, this change may affect governance continuity and decision-making capacity and should be verified.
Positive Indicators
- The company is active and not in liquidation, administration, or receivership.
- Accounts and confirmation statement filings are not overdue.
- It forms part of a group structure (audit exemption subsidiary; corporate PSC with over 75% voting rights), which may imply access to group resources.
- Incorporated in 2015, indicating an established corporate history.
Due Diligence Notes
- Obtain the latest filed annual accounts to review fixed assets, current assets, current liabilities, net assets, and shareholders’ funds.
- Identify any intercompany balances with Quantum Pharma Group Limited, including loans, guarantees, or amounts payable or receivable.
- Confirm the reason for the recent director resignation and assess whether the remaining directors can maintain adequate governance.
- Verify whether the company holds any material property, investments, or other assets despite its non-trading classification.
- Review the group structure for any cross-guarantees, funding arrangements, or dependency provisions affecting the company’s obligations.